TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05818982
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan, intravenous drip, 140-180mg/㎡, D1, Q14D
Study: NCT05171894
Drug: Hemopfin+Green Light
Normalized name: light green SF yellowish
DrugBank: Light green SF yellowish (DB11183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All qualified subjects randomized to Hemoporfin PDT treatment to receive up to 3 cycles of treatment.
Study: NCT06293144
Drug: Ciprofol
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofol was injected intravenously, and was pumped during operation to maintain sedation
Study: NCT06327451
Drug: Atorvastatin 20mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liptor is a capsule in the form of 20 mg, once daily.
Study: NCT05287503
Drug: Ambroxol Hydrochloride
Normalized name: AMBROXOL HYDROCHLORIDE
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Ambroxol hydrochloride 200 mg plus excipients. The manufacturing process of the 200 mg Ambroxol hydrochloride tablets will be performed by wet granulation, drying, mixing and compression to the target final weight.
Study: NCT04701034
Drug: Human Albumin Solution
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.
Study: NCT04958382
Drug: ciprofol
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of ciprofol at 0.12 mg/kg, followed by 0.4-1.6 mg/kg/h for maintenance
Study: NCT04485416
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eltrombopag is an orally administered small-molecule nonpeptide TPO-R agonist.
Study: NCT06580327
Drug: programmed intermittent Bolus epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the study group protocol for pain maintenance, i.e., a programmed intermittent bolus of 10 ml of 0.1% bupivacaine and 2 μg/ml fentanyl every hour until the completion of labor and suturing of the incision. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score \>30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study.
Study: NCT01161394
Drug: Pioglitazone 15mg
Normalized name: METFORMIN 500MG/PIOGLITAZONE 15MG TAB
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01161394
Drug: pioglitazone 30mg
Normalized name: GLIMEPIRIDE 2MG/PIOGLITAZONE 30MG TAB
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05002114
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical CBD cream - special formulation
Study: NCT04998812
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-partum dosing and treatment duration are at the discretion of the physicians, in accordance with local clinical practice and local labelling.
Study: NCT04819906
Drug: Estetrol 20 mg
Normalized name: estetrol
DrugBank: Estetrol (DB12235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One estetrol monohydrate (E4) 20 mg tablet plus four matching placebo tablets orally once
Study: NCT04819906
Drug: Estetrol 100 mg
Normalized name: estetrol
DrugBank: Estetrol (DB12235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Five estetrol monohydrate (E4) 20 mg tablets orally once
Study: NCT06397222
Drug: Sin-Bev-SIRT
Normalized name: Sirturo
DrugBank: Bedaquiline (DB08903)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sintilimab 200mg I.V. q3w and bevacizumab 7.5mg/kg I.V. q3w will be started at 3-7 days after the first SIRT. Treatment of sintilimab and bevacizumab will last up to 24 months. Patients will be allowed to have sintilimab or bevacizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
Study: NCT05654194
Drug: Azacitidine Combined With Venetoclax and ATRA group
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AZA 75mg/m² per day for days 1-7 and venetoclax 100mg orally for day 2 , 200mg orally for day 3, 300mg orally for day4-6, 400mg orally for day7-10,ATRA 45mg/m² for day 12-28,every 28 days for up to 2 cycles as the inductive therapy.ATRA 45mg/m2 per day for d1-21 ,AZA 70mg/m² per day for days 1-7, every 28 days for up to 4 cycles for consolidate therapy.ATRA 45mg/m2 for d1-21 every 28 days,AZA 70mg/m² per day for days 1-7, every 3 month for Maintenance therapy
Study: NCT05085782
Drug: Propranolol Hydrochloride
Normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 weekly doses (40 to 80 mg) 1h before the reactivation procedure
Study: NCT05294835
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketamine infusion
Study: NCT06347718
Drug: anti-CD19 CAR T cell therapy
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Anti-CD7 CAR T-cell therapy (DB18128)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose
Study: NCT00433277
Drug: twice-daily dosage with 0.5% cyclosporine-A eyedrops
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04819906
Drug: Moxifloxacin 400 mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One moxifloxacin 400 mg tablet orally once (open-label)
Study: NCT05045313
Drug: Warfarin sodium tablets
Normalized name: Warfarin Sodium Tablets
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Warfarin sodium, tablet, oral
Study: NCT05045313
Drug: Digoxin tablet
Normalized name: Digoxin Tablets
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Digoxin, tablet, oral
Study: NCT05045313
Drug: Probenecid tablets
Normalized name: Probenecid Tablets
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Probenecid, tablet, oral
Study: NCT05066789
Drug: Duration of DAPT
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1:1 randomization to 1-month DAPT thereafter prasugrel monotherapy and 12-month DAPT (aspirin + prasugrel)
Study: NCT05272865
Drug: Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Assessment of Pharmacokinetic and pharmacodynamic profile of THC oral formulations in 4 arms in healthy volunteers and patients post-chemotherapy.
Study: NCT05112419
Drug: Zibotentan
Normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive a single oral dose of zibotentan capsule under fasted conditions.
Study: NCT05558449
Drug: Midazolam injection
Normalized name: midazolam Injection
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam intravenous injection 1 mg until RASS -3
Study: NCT05281926
Drug: Poly ICLC
Normalized name: Poly iclc
DrugBank: Hiltonol (DB17293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT Poly-ICLC injection (1.0 mg) at Day 1 of weeks 0, 1 and 2. IM Poly-ICLC (20 μg/Kg) at Day 1 and Day 3 of weeks 3, 4, 5 and 6.
Study: NCT06168318
Drug: VH4004280 Formulation A
Normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of VH4004280 Formulation A in fasted or fed conditions.
Study: NCT06168318
Drug: VH4004280 Formulation C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of VH4004280 Formulation C in fasted or fed conditions.
Study: NCT06168318
Drug: VH4004280 Formulation E
Normalized name: E-EPA
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral administration of VH4004280 Formulation E in fasted or fed conditions.
Study: NCT06330519
Drug: Dexamethasone sodium phosphate injection
Normalized name: Dexamethasone Sodium Phosphate Injection
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive 0.8ml of dexamethazone by periodontal ligament injection 30 minutes before the inferior alveolar nerve block
Study: NCT05234320
Drug: Vehicle (Placebo)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive active drug or placebo in addition to standard of care
Study: NCT05234320
Drug: Standard of core (type of therapy is depend of decide of the site)
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive active drug or placebo in addition to standard of care
Study: NCT04754802
Drug: PH94B Nasal Spray
Normalized name: PH94B
DrugBank: PH94B (DB04968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray delivered 20 minutes before the public speaking stressor
Study: NCT04840784
Drug: ETH-155008
Normalized name: ETH
DrugBank: Ethionamide (DB00609)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.~Dosage form:10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal.
Study: NCT04417049
Drug: Pentoxifylline 400 MG
Normalized name: pentoxifylline 400 MG
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will be provided with pentoxifylline 400 mg to be orally ingested twice daily for 8 weeks.
Study: NCT05754424
Drug: AT278
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concentrated rapid acting insulin aspart
Study: NCT05754424
Drug: NovoRapid
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rapid-acting insulin aspart
Study: NCT05840094
Drug: 18F-FDG
Normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18F-FDG is injected intravenously with a dose of 0.1mCi/kg.
Study: NCT05871333
Drug: Losartan 50mg Tab
Normalized name: LOSARTAN 50MG TAB
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan 50 mg oral tablets
Study: NCT05201638
Drug: IMU-838 tablets
Normalized name: LACTOBACILLUS HELVETICUS 1.50 g in 150 mL / RICE BRAN 1.50 g in 150 mL TOPICAL AEROSOL, FOAM [IMU]
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are randomized to IMU-838 or placebo in ratio 1:1
Study: NCT04521803
Drug: high dose Rifampicin (RIF)
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulations were performed to determine the dose of RIF required to achieve the most equitable drug exposures across the weight range, 30 to 100 kg. Demographic data of a reference cohort of TB patients (n = 1225), with or without HIV-1 coinfection, recruited in clinical trials conducted in West Africa and South Africa were used for the simulations35-38. An additional 12 250 virtual patients were generated using the weight and height distributions of the 1225 patients to increase the number of patients with a weight close to the boundaries of the weight range. Parameter estimates of the population PK model for RIF were used to simulate (100 replicates) RIF exposures22. Four dosing scenarios were evaluated using the weight-band based dosing with 4-drug FDC tablets and extra RIF tablets with each tablet containing 150 mg or 600 mg RIF. The FDC tablets were assumed to have 20% reduced bioavailability based on data from a clinical trial where the same formulation was used
Study: NCT05021887
Drug: Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT05021887
Drug: FLOVENT DISKUS
Normalized name: Flovent Diskus
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT06467565
Drug: Liposomal irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NALIRIFOX（Oxaliplatin 60 mg/m2 IV over 2 hours ; Liposomal Irinotecan 50 mg/m2 IV over 90 minutes ; Leucovorin(l-LV) 400 mg/m2 IV over 2 hours 5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion） on days 1 of a 14-day cycle.
Study: NCT04599712
Drug: Amivantamab
Normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amivantamab will be administered intravenously at the recommended doses based on weight (1050 milligram \[mg\] or 1400 mg) once weekly for the first 4 week cycle (1 cycle equals to 28 days), then every 2 weeks thereafter.
Study: NCT04944082
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (The same remdesivir dose as mentioned + ivermectin 4 tablet (6mg) once daily before meal for four days)
Study: NCT04845646
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg/capsule
Study: NCT06615869
Drug: Molnupiravir
Normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral Administration.
Study: NCT05042440
Drug: Efanesoctocog alfa
Normalized name: Efanesoctocog alfa
DrugBank: Efanesoctocog alfa (DB16662)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection Intravenous
Study: NCT05042440
Drug: Octocog alfa
Normalized name: Octocog alfa
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Solution for injection Intravenous
Study: NCT05042440
Drug: Rurioctocog alfa pegol
Normalized name: rurioctocog alfa pegol
DrugBank: Rurioctocog alfa pegol (DB16007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection Intravenous
Study: NCT05022563
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin-based
Study: NCT05022563
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban
Study: NCT05022563
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban
Study: NCT05022563
Drug: Dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran
Study: NCT05022563
Drug: Edoxaban
Normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Edoxaban
Study: NCT06616922
Drug: Levofloxacin 0.5% eye drops solution (Oftaquix®)
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop, 8 times a day (approximately every 2 hours while awake) on Days 1 and 2, and 1 drop, 4 times a day (approximately every 4 hours while awake) on Days 3 through 5.
Study: NCT04647383
Drug: Lemborexant 10 mg
Normalized name: lemborexant 10 MG
DrugBank: Lemborexant (DB11951)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
Study: NCT04647383
Drug: Lemborexant 10 mg
Normalized name: lemborexant 10 MG
DrugBank: Lemborexant (DB11951)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: COPD: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes before lights off) or at home when not in the clinic.
Study: NCT04995120
Drug: chemotherapy TP regimen combined with Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.~Response rate of primary tumor is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If overall response rate of primary tumor is complete response or partial response, then chemoradiation is conducted, followed by maintenance therapy of Toripalimab for 8 cycles (6 months). Otherwise, surgery is conducted (laryngeal preservation surgery is preferred), followed by adjuvant radiation/chemoradiation and then maintenance therapy of Toripalimab for 8 cycles.
Study: NCT04858659
Drug: PK101
Normalized name: Pimavanserin
DrugBank: Pimavanserin (DB05316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet at each time, 2 times a day
Study: NCT05470829
Drug: ZM-H1505R
Normalized name: ZM-39923
DrugBank: ZM-39923 (DB17064)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 dosage form:75mg dosage:Tablet frequency: Quaque die duration: Day1; Day 4\~ Day 14~Cohort 1 of Part 2 dosage form:50mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 2 of Part 2 dosage form:100mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28~Cohort 3 of Part 2 dosage form:200mg dosage:Tablet frequency: Quaque die duration: Day 1\~ Day 28
Study: NCT05752916
Drug: rhTNK-tPA
Normalized name: tPA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant human TNK tissue-type plasminogen activator. Patients will receive intravenous rhTNK-tPA (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).
Study: NCT05896969
Drug: SNK-396 - SAD cohort
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of SNK-396 within the dose range of 25 to 800 mg, or matching placebo.
Study: NCT05150418
Drug: Oxygen gas
Normalized name: oxygen Gas for Inhalation
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxygen 15 l/min
Study: NCT05150418
Drug: Air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room air 15 l/min
Study: NCT00881413
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous esomeprazole (Nexium®, AstraZeneca, Sodertalje, Sweden) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral esomeprazole 40 mg (Nexium®, AstraZeneca, Sodertalje, Sweden) for 2 months
Study: NCT00881413
Drug: Pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After successful endoscopy, intravenous pantoprazole (Pantoloc®, Nycomed GMBH, Konstanz, Germany) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral pantoprazole 40 mg (Pantoloc®, Nycomed GMBH, Oranienburg, Germany) for 2 months
Study: NCT04689347
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5 mg/kg intravenous infusion every 2 weeks
Study: NCT04689347
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: irinotecan 165 mg/sqm intravenous infusion every 2 weeks
Study: NCT04689347
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral temozolomide with progressive dose escalation at inter-patient level over days 1-5 every 28 days. (75 mg/sqm; 100 mg/sqm; 125 mg/sqm or 150 mg/sqm)
Study: NCT05113459
Drug: Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy
Normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: disitamab vedotin：2.5mg/kg, iv,d1,q2w,6cycle PD-1(Sintilimab ):200mg,iv,d1,q2w,6cycle Capecitabine:1000mg/m2,po,bid,d1-14,q3w,4cycle
Study: NCT06445946
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Individuals randomized to this arm will receive oral metformin tablets for their Gestational diabetes mellitus treatment.
Study: NCT06445946
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individuals randomized to this arm will receive injectable insulin for their Gestational diabetes mellitus treatment.
Study: NCT05150756
Drug: Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE]
Normalized name: Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At induction of anesthesia, patients will receive a loading dose of 1.5mg/kg lidocaine hydrochloride 2% slowly over 3 min followed by IV infusion of 2mg/kg/hr lidocaine hydrochloride 2% till the end of surgery
Study: NCT05150756
Drug: morphine sulphate (10mg/ ml ampoule)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At induction of anesthesia, patients will receive a loading dose of IV 0.1mg/kg morphine sulphate slowly over 3 minutes followed by IV infusion of normal saline via infusion pump. The infusion will be continued till the end of surgery
Study: NCT06160414
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive Metformin orally, after fasting.